Categories
Search
On-Line Support
GP Clomiphene (Clomid)
USD 18.00
USD 18.00
-
GP Clomiphene (Clomid)
Geneza Pharmaceuticals1 x 30 tabs » 50 mg/tab
General information:
Manufacturer: Geneza Pharmaceuticals
Substance: Clomiphene Citrate
(GP Clomiphene/Clomid)
Pack: 30
tabs (50 mg/tab)
GP Clomiphene/Clomid is a triphenylethylene derivative distantly related to diethylstilbestrol. It acts as a selective estrogen receptor modulator, similar to tamoxifen and raloxifene. All three drugs are competitive inhibitors of estrogen binding to estrogen receptors and have mixed agonist and antagonist activity depending upon the target tissue.
The commercially available form of GP Clomiphene/Clomid is the dihydrogen citrate salt (clomiphene citrate). It contains two stereoisomers: zu- clomiphene (38 percent) and en-clomiphene (62 percent), which were originally called the cis-isomer and trans-isomer, respectively. En-clomiphene is cleared rapidly, while zu-clomiphene has a long half-life. The two clomiphene isomers have mixed estrogenic and antiestrogenic effects that vary among species. Zu- clomiphene appears to have greater estrogenic activity than en-clomiphene .
14C-labeled clomiphene citrate is absorbed by the gastrointestinal tract. Fifty percent of the oral dose is excreted after five days, but radioactivity from labeled clomiphene appears in the feces up to six weeks after administration. However, the pharmacologic effect of clomiphene citrate is brief.
SIDE EFFECTS
Side effects of clomiphene include:
-Ovarian hyperstimulation, ranging from mild, with enlarged ovaries and abdominal discomfort, to moderate, additionally causing nausea, vomiting, or shortness of breath, to severe and life-threatening.
- Hot flashes
-Irritability
- Nausea, abdominal pain
- Headaches
- Thick cervical mucus, which sperm cannot travel through. This can be reversed with medicine or bypassed with intrauterine insemination
-Breast tenderness
-Blurred vision
- Hair loss (very rare)
Women who become pregnant after clomiphene therapy have an approximately 5% to 8% chance of multiple pregnancy. 3 This compares to a 1% to 2% chance in the general North American and European population. 2 Multiples resulting from clomiphene treatment are almost exclusively twins. Triplets are rare.
The commercially available form of GP Clomiphene/Clomid is the dihydrogen citrate salt (clomiphene citrate). It contains two stereoisomers: zu- clomiphene (38 percent) and en-clomiphene (62 percent), which were originally called the cis-isomer and trans-isomer, respectively. En-clomiphene is cleared rapidly, while zu-clomiphene has a long half-life. The two clomiphene isomers have mixed estrogenic and antiestrogenic effects that vary among species. Zu- clomiphene appears to have greater estrogenic activity than en-clomiphene .
14C-labeled clomiphene citrate is absorbed by the gastrointestinal tract. Fifty percent of the oral dose is excreted after five days, but radioactivity from labeled clomiphene appears in the feces up to six weeks after administration. However, the pharmacologic effect of clomiphene citrate is brief.
SIDE EFFECTS
Side effects of clomiphene include:
-Ovarian hyperstimulation, ranging from mild, with enlarged ovaries and abdominal discomfort, to moderate, additionally causing nausea, vomiting, or shortness of breath, to severe and life-threatening.
- Hot flashes
-Irritability
- Nausea, abdominal pain
- Headaches
- Thick cervical mucus, which sperm cannot travel through. This can be reversed with medicine or bypassed with intrauterine insemination
-Breast tenderness
-Blurred vision
- Hair loss (very rare)
Women who become pregnant after clomiphene therapy have an approximately 5% to 8% chance of multiple pregnancy. 3 This compares to a 1% to 2% chance in the general North American and European population. 2 Multiples resulting from clomiphene treatment are almost exclusively twins. Triplets are rare.
